welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: March 1, 2003
estimated completion: Not Available
last updated: September 29, 2017
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Nutritional Agents With Anti-inflammatory Properties in Chemoprevention of Colorectal NeoplasiaThe strong link between inflammation and...
8 Myths About Ostomies DebunkedMore than 750,000 Americans live with an...
Impact of a Hospital-based Register on the Management of Familial Adenomatous PolyposisColorectal cancer in familial adenomatou...
Colorectal Cancer in Primary Care: Recognizing and Reducing RiskA vast amount of information exists rega...
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous PolyposisColorectal cancer (CRC) is a leading cau...
Chemoprevention of Colorectal NeoplasiaBACKGROUND : Colorectal cancer is a comm...
New Clinical Trials Offer Hope in Two Rare Genetic DiseasesIn 1994, three of Cindy Parseghian’s f...